Merck Strikes Back In Fosamax Case

Law360, New York (November 14, 2007, 12:00 AM EST) -- As new suits continue to pour into the courts, Merck & Co. has formally shot back in its multidistrict, product liability war over Fosamax, denying all allegations lodged against the osteoporosis medication.

On Tuesday, the pharmaceutical giant filed its formal answer and affirmative defenses in the U.S. District Court for the Southern District of New York, rejecting, among others, the negligence and strict liability charges that have been hurled in connection with Fosamax.

“Merck denies each and every allegation of Paragraph 74, and respectfully refers the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.